

Oral Presentation – Abstract O235

Major challenges in clinical management of TB/HIV co-infected patients in Eastern Europe compared with Western Europe and Latin America

Efsen, Anne Marie¹; Schultze, Anna²; Post, Frank³; Pantelev, Alexander⁴; Furrer, Hansjakob⁵; Miller, Robert⁶; Skrahin, Aliaksandr⁷; Losso, Marcelo H⁸; Toibaro, Javier⁸; Girardi, Enrico⁹; Miro, José¹⁰; Bruyand, Mathias¹¹; Obel, Niels^{1,2}; Caylá, Joan¹⁰; Podlekareva, Daria¹; Lundgren, Jens¹; Mocroft, Amanda² and Kirk, Ole¹, EuroCoord TB/HIV Study Group¹

¹Department of Infectious Diseases and Rheumatology, CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. ²Department of Infection and Population Health, University College London, London, UK. ³Department of Sexual Health, King's College Hospital, London, UK. ⁴City TB Hospital 2, HIV/TB, St. Petersburg, Russian Federation. ⁵Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland. ⁶Centre for Sexual Health and HIV Research, University College London, London, UK. ⁷Republican Research and Practical Centre for Pulmonary and TB, Clinical Department, Minsk, Belarus. ⁸Hospital Gral. de Agudos JM Ramos Mejía, Servicio Inmunocomprometidos, Buenos Aires, Argentina. ⁹Istituto Nazionale Malattie Infettive L. Spallanzani – IRCCS, UOC Epidemiologia Clinica, Rome, Italy. ¹⁰Hospital Clinic Universitari de Barcelona, Hospital Clinic Universitari, Barcelona, Spain. ¹¹Université Bordeaux Segalen, INSERM U897, Bordeaux, France.

Introduction: Rates of both TB/HIV co-infection and multi-drug-resistant (MDR) TB are increasing in Eastern Europe (EE). Data on the clinical management of TB/HIV co-infected patients are scarce. Our aim was to study the clinical characteristics of TB/HIV patients in Europe and Latin America (LA) at TB diagnosis, identify factors associated with MDR-TB and assess the activity of initial TB treatment regimens given the results of drug-susceptibility tests (DST).

Materials and Methods: We enrolled 1413 TB/HIV patients from 62 clinics in 19 countries in EE, Western Europe (WE), Southern Europe (SE) and LA from January 2011 to December 2013. Among patients who completed DST within the first month of TB therapy, we linked initial TB treatment regimens to the DST results and calculated the distribution of patients receiving 0, 1, 2, 3 and ≥ 4 active drugs in each region. Risk factors for MDR-TB were identified in logistic regression models.

Results: Significant differences were observed between EE ($n = 844$), WE ($n = 152$), SE ($n = 164$) and LA ($n = 253$) for use of combination antiretroviral therapy (cART) at TB diagnosis (17%, 40%, 44% and 35%, $p < 0.0001$), a definite TB diagnosis (culture and/or PCR positive for *Mycobacterium tuberculosis*; 47%, 71%, 72% and 40%, $p < 0.0001$) and MDR-TB prevalence (34%, 3%, 3% and 11%, $p < 0.0001$ among those with DST results). The history of injecting drug use [adjusted OR (aOR) = 2.03, (95% CI 1.00–4.09)], prior TB treatment (aOR = 3.42, 95% CI 1.88–6.22) and living in EE (aOR = 7.19, 95% CI 3.28–15.78) were associated with MDR-TB. For 569 patients with available DST, the initial TB treatment contained ≥ 3 active drugs in 64% of patients in EE compared with 90–94% of patients in other regions (Figure 1a). Had the patients received initial therapy with standard therapy [Rifampicin, Isoniazid, Pyrazinamide, Ethambutol (RHZE)], the corresponding proportions would have been 64% vs. 86–97%, respectively (Figure 1b).

Conclusion: In EE, TB/HIV patients had poorer exposure to cART, less often a definitive TB diagnosis and more often MDR-TB compared to other parts of Europe and LA. Initial TB therapy in EE was sub-optimal, with less than two-thirds of patients receiving at least three active drugs, and improved compliance with standard RHZE treatment does not seem to be the solution. Improved management of TB/HIV patients requires routine use of DST, initial TB therapy according to prevailing resistance patterns and more widespread use of cART.

Published 2 November 2014

Copyright: © 2014 Efsen AM et al; licensee International AIDS Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 Unported (CC BY 3.0) License (<http://creativecommons.org/licenses/by/3.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.




Figure 1. Susceptibility of initial TB treatment.